^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Bavencio (avelumab)

    i
    Company:
    EMD Serono
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Apply
    QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL (NCT03169790)
    Phase 1/2
    ImmunityBio, Inc.
    Withdrawn
    Last update posted :
    02/24/2025
    Initiation :
    12/01/2017
    Primary completion :
    01/01/2019
    Completion :
    12/23/2021
    CD20
    |
    CD20 positive
    |
    Avastin (bevacizumab) • Rituxan (rituximab) • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • oxaliplatin • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-061 • NK92-CD16-158V • cyclophosphamide intravenous
    QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (NCT03554109)
    Phase 2
    ImmunityBio, Inc.
    Withdrawn
    Last update posted :
    02/21/2025
    Initiation :
    09/01/2018
    Primary completion :
    06/01/2020
    Completion :
    02/09/2022
    HER-2 • ER • PGR
    |
    HER-2 overexpression • HER-2 amplification
    |
    5-fluorouracil • Bavencio (avelumab) • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)
    Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (NCT04068194)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    04/07/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    TMB
    |
    Bavencio (avelumab) • peposertib (M3814)
    Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors (NCT04266912)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    03/17/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC
    |
    Bavencio (avelumab) • berzosertib (M6620)
    Avelumab with or Without Cetuximab in Treating Patients with Advanced Skin Squamous Cell Cancer (NCT03944941)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    06/17/2019
    Primary completion :
    12/01/2026
    Completion :
    12/01/2028
    PD-L1 • CD4
    |
    Erbitux (cetuximab) • Bavencio (avelumab)
    Feasibility and Safety of IMP321 (eftilagimod Alpha) for Advanced Stage Solid Tumors (INSIGHT) (NCT03252938)
    Phase 1
    Institut für Klinische Krebsforschung IKF GmbH ...
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    08/15/2017
    Primary completion :
    09/30/2025
    Completion :
    09/30/2025
    PD-L1
    |
    Bavencio (avelumab) • ImmuFact (eftilagimod alpha)
    Avelumab With Radiotherapy in Patients With Leptomeningeal Disease (NCT03719768)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Completed
    Last update posted :
    02/12/2025
    Initiation :
    06/10/2019
    Primary completion :
    07/19/2022
    Completion :
    08/21/2024
    CTLA4
    |
    Bavencio (avelumab)
    DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer. (SELECTIO-UC) (NCT06820255)
    Phase 4
    Fondazione Policlinico Universitario Agostino G...
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    01/07/2025
    Primary completion :
    01/07/2026
    Completion :
    01/07/2027
    HER-2 • PD-L1 • NECTIN4 • TACSTD2
    |
    PD-L1 expression • HER-2 expression
    |
    cisplatin • carboplatin • gemcitabine • Bavencio (avelumab)
    A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy (NCT03076554)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    04/19/2017
    Primary completion :
    06/30/2025
    Completion :
    06/30/2026
    PD-L1
    |
    Bavencio (avelumab)
    Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study (NCT05092958)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    06/03/2022
    Primary completion :
    12/10/2025
    Completion :
    12/10/2025
    IFNA1
    |
    Bavencio (avelumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    Avelumab in First-line NSCLC (JAVELIN Lung 100) (NCT02576574)
    Phase 3
    EMD Serono Research & Development Institute, Inc.
    Completed
    Last update posted :
    01/31/2025
    Initiation :
    10/29/2015
    Primary completion :
    12/06/2021
    Completion :
    01/29/2024
    PD-L1
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • gemcitabine • paclitaxel • Bavencio (avelumab) • pemetrexed
    TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (NCT02693535)
    Phase 2
    American Society of Clinical Oncology
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/14/2016
    Primary completion :
    06/30/2026
    Completion :
    06/30/2027
    BRAF
    |
    ER positive • HER-2 negative • PGR positive
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • Torisel (temsirolimus) • letrozole • Inlyta (axitinib) • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension
    QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (NCT03228667)
    Phase 2
    ImmunityBio, Inc.
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    12/11/2018
    Primary completion :
    08/31/2029
    Completion :
    12/31/2030
    BRAF • ALK • MSI
    |
    PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • docetaxel • Bavencio (avelumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    Avelumab in G2-3 NET (NET-002) (NCT03278379)
    Phase 2
    Sunnybrook Health Sciences Centre
    Completed
    Last update posted :
    12/24/2024
    Initiation :
    11/15/2017
    Primary completion :
    07/26/2021
    Completion :
    07/06/2023
    PD-L1 • TMB
    |
    Bavencio (avelumab)
    The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer (NCT03414658)
    Phase 2
    Adrienne G. Waks
    Active, not recruiting
    Last update posted :
    11/06/2024
    Initiation :
    06/21/2018
    Primary completion :
    05/01/2023
    Completion :
    05/31/2025
    HER-2 • PD-L1
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Bavencio (avelumab) • vinorelbine tartrate • utomilumab (PF-05082566)
    Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study (NCT03244176)
    Phase 1
    Austin Health
    Active, not recruiting
    Last update posted :
    07/30/2024
    Initiation :
    07/21/2017
    Primary completion :
    06/16/2022
    Completion :
    07/01/2025
    CD20
    |
    CD20 positive
    |
    Rituxan (rituximab) • Bavencio (avelumab) • doxorubicin hydrochloride • cyclophosphamide
    The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy (NCT03737721)
    Phase 2
    AHS Cancer Control Alberta
    Active, not recruiting
    Last update posted :
    06/14/2024
    Initiation :
    04/12/2019
    Primary completion :
    11/21/2022
    Completion :
    12/08/2024
    PD-L1
    |
    Bavencio (avelumab)
    AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma (AMPLIFY-NEOVAC) (NCT03893903)
    Phase 1
    German Cancer Research Center
    Active, not recruiting
    Last update posted :
    06/05/2024
    Initiation :
    10/19/2018
    Primary completion :
    09/01/2024
    Completion :
    12/01/2024
    ATRX
    |
    IDH1 R132
    |
    Bavencio (avelumab) • IDH1R132H peptide vaccine
    Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) (LUNG-MAP Sub-Study) (NCT04173507)
    Phase 2
    SWOG Cancer Research Network
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    02/14/2020
    Primary completion :
    11/24/2021
    Completion :
    07/01/2024
    STK11
    |
    STK11 mutation
    |
    Bavencio (avelumab) • Talzenna (talazoparib)
    Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe) (NCT03971409)
    Phase 2
    Hope Rugo, MD
    Recruiting
    Last update posted :
    05/13/2024
    Initiation :
    07/08/2019
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    HER-2 • PD-L1 • ER • PGR
    |
    HER-2 negative
    |
    Bavencio (avelumab) • Mektovi (binimetinib) • pegylated liposomal doxorubicin • Trodelvy (sacituzumab govitecan-hziy) • utomilumab (PF-05082566) • ivuxolimab (PF-04518600)
    Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI (NCT04954599)
    Phase 1/2
    Maastricht University Medical Center
    Recruiting
    Last update posted :
    04/22/2024
    Initiation :
    04/25/2023
    Primary completion :
    02/01/2026
    Completion :
    05/01/2026
    BRCA1 • BRCA2
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • Imfinzi (durvalumab) • Bavencio (avelumab) • Libtayo (cemiplimab-rwlc) • CP-506
    Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer (NCT02912572)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    04/19/2024
    Initiation :
    11/14/2016
    Primary completion :
    03/01/2025
    Completion :
    03/01/2027
    MSI • POLE • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR • POLE mutation • MSH6 expression
    |
    Bavencio (avelumab) • Talzenna (talazoparib) • Inlyta (axitinib)
    Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma (I-MAT) (NCT04291885)
    Phase 2
    Melanoma and Skin Cancer Trials Limited
    Recruiting
    Last update posted :
    04/15/2024
    Initiation :
    10/26/2020
    Primary completion :
    04/01/2027
    Completion :
    04/01/2028
    TMB
    |
    PD-L1 expression
    |
    Bavencio (avelumab)
    Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy (NCT03558139)
    Phase 1
    Gilead Sciences
    Completed
    Last update posted :
    04/01/2024
    Initiation :
    05/23/2018
    Primary completion :
    12/03/2020
    Completion :
    12/03/2020
    PD-L1
    |
    PD-L1 expression
    |
    Bavencio (avelumab) • magrolimab (ONO-7913)
    Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (NCT03440567)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    03/29/2024
    Initiation :
    04/02/2018
    Primary completion :
    12/30/2024
    Completion :
    12/30/2024
    CD20 • CCND1
    |
    CD20 positive
    |
    carboplatin • Imbruvica (ibrutinib) • Rituxan (rituximab) • Bavencio (avelumab) • cyclophosphamide • ifosfamide • etoposide IV • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • utomilumab (PF-05082566) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous
    Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (ImmunoADAPT) (NCT03573648)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    03/27/2024
    Initiation :
    11/13/2018
    Primary completion :
    07/31/2024
    Completion :
    12/31/2025
    ER
    |
    ER positive
    |
    Ibrance (palbociclib) • tamoxifen • Bavencio (avelumab) • Eligard (leuprolide acetate) • goserelin acetate
    Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer (ATTAC-MCC) (NCT03747484)
    Phase 1/2
    Fred Hutchinson Cancer Center
    Active, not recruiting
    Last update posted :
    03/26/2024
    Initiation :
    07/03/2019
    Primary completion :
    01/10/2024
    Completion :
    01/10/2025
    HLA-A
    |
    HLA-A*02
    |
    Keytruda (pembrolizumab) • Bavencio (avelumab) • Actimmune (interferon gamma-1 b) • MCC1 TCR
    Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies (NCI-2018-01118) (NCT03217747)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    03/25/2024
    Initiation :
    08/02/2017
    Primary completion :
    09/30/2024
    Completion :
    09/30/2024
    CD8
    |
    Bavencio (avelumab) • utomilumab (PF-05082566) • ivuxolimab (PF-04518600)
    Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (A-Brave) (NCT02926196)
    Phase 3
    Istituto Oncologico Veneto IRCCS
    Active, not recruiting
    Last update posted :
    03/21/2024
    Initiation :
    06/17/2016
    Primary completion :
    06/01/2024
    Completion :
    10/01/2025
    HER-2
    |
    PD-L1 expression • HER-2 amplification • HER-2 negative • HR negative
    |
    Bavencio (avelumab)
    Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY) (NCT04841148)
    Phase 2
    Abramson Cancer Center at Penn Medicine
    Recruiting
    Last update posted :
    03/12/2024
    Initiation :
    06/01/2021
    Primary completion :
    11/01/2024
    Completion :
    05/01/2028
    HER-2 • ER • PGR
    |
    ER negative • PGR positive
    |
    Ibrance (palbociclib) • Bavencio (avelumab) • hydroxychloroquine
    Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer (NCI-2018-02517) (NCT03744793)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    03/06/2024
    Initiation :
    04/11/2019
    Primary completion :
    01/31/2025
    Completion :
    01/31/2025
    MTAP • IL17A
    |
    cisplatin • Bavencio (avelumab) • pemetrexed
    A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (NCT03845166)
    Phase 1
    Exelixis
    Active, not recruiting
    Last update posted :
    02/19/2024
    Initiation :
    03/20/2019
    Primary completion :
    11/01/2024
    Completion :
    11/01/2024
    HER-2 • KRAS • BRAF • NRAS • MSI
    |
    BRAF V600E • HR positive • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type
    |
    Tecentriq (atezolizumab) • Bavencio (avelumab) • zanzalintinib (XL092)
    Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies (NCT04902040)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/14/2024
    Initiation :
    04/14/2021
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • plinabulin (BPI 2358)
    Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study (NCT03891238)
    Phase 2
    Consorzio Oncotech
    Completed
    Last update posted :
    02/01/2024
    Initiation :
    02/06/2019
    Primary completion :
    09/15/2021
    Completion :
    09/15/2021
    PD-L1 • PD-1
    |
    PD-L1 expression • PD-1 expression
    |
    cisplatin • Bavencio (avelumab)
    CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy (CAVE 2) (NCT05291156)
    Phase 2
    University of Campania "Luigi Vanvitelli&q...
    Recruiting
    Last update posted :
    02/01/2024
    Initiation :
    07/21/2022
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    KRAS • BRAF
    |
    BRAF wild-type • KRAS exon 2 mutation
    |
    Erbitux (cetuximab) • Bavencio (avelumab)
    Palbociclib After CDK and Endocrine Therapy (PACE) (NCT03147287)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    01/11/2024
    Initiation :
    09/05/2017
    Primary completion :
    12/31/2022
    Completion :
    12/31/2024
    HER-2 • PGR
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Ibrance (palbociclib) • Bavencio (avelumab) • fulvestrant
    A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) (NCT02684006)
    Phase 3
    Pfizer
    Active, not recruiting
    Last update posted :
    12/22/2023
    Initiation :
    03/23/2016
    Primary completion :
    08/31/2023
    Completion :
    05/21/2024
    PD-L1
    |
    PD-L1 expression
    |
    sunitinib • Bavencio (avelumab) • Inlyta (axitinib)
    PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer (NCT04360941)
    Phase 1
    Royal Marsden NHS Foundation Trust
    Recruiting
    Last update posted :
    12/22/2023
    Initiation :
    08/11/2020
    Primary completion :
    07/31/2025
    Completion :
    12/31/2025
    PD-L1 • PIK3CA • TMB • PTEN • RB1
    |
    PD-L1 expression • PIK3CA mutation • PD-L1 negative • RB1 mutation • PTEN expression • PIK3CA expression • PIK3CA mutation + PTEN mutation
    |
    Ibrance (palbociclib) • Bavencio (avelumab)
    Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas (NCT03783936)
    Phase 2
    Ashwin Somasundaram
    Completed
    Last update posted :
    12/19/2023
    Initiation :
    01/24/2019
    Primary completion :
    09/11/2020
    Completion :
    08/30/2022
    HER-2
    |
    HER-2 amplification
    |
    Herceptin (trastuzumab) • 5-fluorouracil • Bavencio (avelumab) • oxaliplatin • leucovorin calcium
    Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study (AVENuE) (NCT03617666)
    Phase 2
    University College, London
    Active, not recruiting
    Last update posted :
    12/12/2023
    Initiation :
    09/27/2019
    Primary completion :
    07/04/2022
    Completion :
    05/30/2025
    PD-1
    |
    PD-1 expression
    |
    Bavencio (avelumab)